Left ventricular hypertrophy in daily dialysis

Miner Electrolyte Metab. Jan-Apr 1999;25(1-2):90-4. doi: 10.1159/000057427.


Cardiac hypertrophy, a well-known independent risk factor for cardiovascular death, is a very frequent complication in ESRD patients. Its frequency tends to be even higher in dialyzed patients due to the fact that the current dialytic treatments are unable to keep under a satisfactory control the various responsible factors and particularly the blood pressure, which is largely the most important. Daily hemodialysis, a more frequent schedule consisting of 6-7 sessions/week lasting 2 or more hours, has definitely proved its superiority in controlling blood pressure and in improving anemia, and thus has the requisites for positively influencing cardiac hypertrophy. In fact, a series of studies, both retrospective and prospective, performed during the last years by our group, have confirmed that this new, more frequent and thus more physiological schedule, is able not only to stop the progression of the cardiac hypertrophy in uremic patients but also to revert toward the normality, in a relatively short time. This appears to be essentially a consequence of the excellent blood pressure control, which in turn derives from the easier control of the true dry weight, achievable with this type of dialytic treatment.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Blood Pressure / physiology
  • Circadian Rhythm / physiology*
  • Cross-Over Studies
  • Echocardiography
  • Female
  • Humans
  • Hypertrophy, Left Ventricular / diagnosis
  • Hypertrophy, Left Ventricular / physiopathology
  • Hypertrophy, Left Ventricular / therapy*
  • Male
  • Middle Aged
  • Prospective Studies
  • Radiography, Thoracic
  • Renal Dialysis*
  • Retrospective Studies